U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Alogliptin Plus Metformin (Kazano) for Type 2 Diabetes Mellitus [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.

Cover of Alogliptin Plus Metformin (Kazano) for Type 2 Diabetes Mellitus

Alogliptin Plus Metformin (Kazano) for Type 2 Diabetes Mellitus [Internet].

Show details

REFERENCES

1.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes [Internet] 2013 Apr;37 suppl 1:S1–S212. [cited 2014 Oct 3]; Available from: http://guidelines​.diabetes​.ca/App_Themes​/CDACPG/resources/cpg_2013_full_en.pdf. [PubMed: 24070926]
2.
Public Health Agency of Canada. Diabetes in Canada: facts and figures from a public health perspective: report highlights [Internet]. Ottawa: PHAC; 2011. [cited 2014 Oct 20]. Available from: http://www​.phac-aspc​.gc.ca/cd-mc/publications​/diabetes-diabete​/facts-figures-faits-chiffres-2011​/highlights-saillants-eng.php.
3.
Canadian Diabetes Association. The prevalence and costs of diabetes [Internet]. Ottawa: CDA; 2012. [cited 2014 Oct 3]. Available from: http://www​.diabetes.ca​/documents/about-diabetes​/PrevalanceandCost_09.pdf.
4.
Health Canada. It's your health: type 2 diabetes. Ottawa: Health Canada; 2005.
5.
Canadian Agency for Drugs and Technologies in Health. Second-line pharmacotherapy for type 2 diabetes - update [Internet]. Ottawa: The Agency; Jul, 2013. [cited 2014 Oct 2]. (CADTH optimal use report; vol.3, no.1a). Available from: http://www​.cadth.ca/media​/pdf/OP0512_DiabetesUpdate​_Second-line_e.pdf. [PubMed: 24278998]
6.
Canadian Agency for Drugs and Technologies in Health. Third-line pharmacotherapy for type 2 diabetes - update [Internet]. Ottawa: The Agency; Jul, 2013. [cited 2014 Oct 2]. (CADTH optimal use report; vol.3, no.1b). Available from: http://www​.cadth.ca/media​/pdf/OP0512_Diabetes​%20Update_Third-line_e.pdf. [PubMed: 27195346]
7.
Ontario Ministry of Health and Long-Term Care. Ontario drug benefit formulary/comparative drug index [Internet]. Toronto: The Ministry; 2014. [cited 2014 Oct 16]. Available from: https://www​.healthinfo​.moh.gov.on.ca/formulary/
8.
Common Drug Review. Indication: type 2 diabetes mellitus [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); Nov 15, 2013. [cited 2014 Sep 24]. CDEC final recommendation: saxagliptin (Onglyza - Bristol-Meyers Squibb Canada and AstraZeneca Canada). Available from: http://www​.cadth.ca/media​/cdr/complete/complete​_SR0329_Onglyza-preNOC​_19-Nov-13_e.pdf.
9.
Common Drug Review. Indication: type 2 diabetes mellitus [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); Jun 23, 2010. [cited 2014 Sep 24]. CEDAC final recommendation: sitagliptin resubmission (Januvia - Merck Frosst Canada Ltd.). Available from: http://www​.cadth.ca/media​/cdr/complete/cdr_complete_Januvia​%20Resubmission​_June-29-2010.pdf.
10.
Common Drug Review. Indication: type 2 diabetes mellitus [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); Feb 15, 2012. [cited 2014 Sep 24]. CDEC final recommendation: linagliptin (Trajenta - Boehringer Ingelheim Canada). Available from: http://www​.cadth.ca/media​/cdr/complete/cdr​_complete_Trajenta_February_18_2012​.pdf.
11.
Common Drug Review. CEDAC final recommendation: sitagliptin/metformin (Janumet - Merck Frosst Canada Ltd.) Indication: type 2 diabetes mellitus [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); Jun 23, 2010. [cited 2014 Oct 20]. Available from: http://www​.cadth.ca/media​/cdr/complete/cdr​_complete_Janumet_June-29-2010.pdf.
12.
Common Drug Review. CDEC final recommendation: linaglitpin/metformin hydrochloride (Jentadueto - Boehringer Ingelheim Canada Ltd.) Indication: type 2 diabetes mellitus [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); Oct 17, 2013. [cited 2014 Oct 20]. Available from: http://www​.cadth.ca/media​/cdr/complete/cdr​_complete_Jentadueto_October-21-13_e​.pdf.
13.
Common Drug Review. CDEC final recommendation: saxagliptin/metformin (Komboglyze - AstraZeneca) Indication: type 2 diabetes mellitus [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); May 21, 2014. [cited 2014 Oct 20]. Available from: http://www​.cadth.ca/media​/cdr/complete/SR0348​_complete_Komboglyze-Jun-24-14.pdf.
14.
PrByetta®: exenatide injection:5 µg/mL, 1.2 ml prefilled pen (60 doses of 5 µg/dose) and 2.4 mL prefilled pen (60 doses of 10 µg/dose) [product monograph]. Mississauga (ON): AstraZeneca Canada Inc; Jun 30, 2014.
15.
PrKazano™: alogliptin (as alogliptin benzoate) and metformin hydrochloride 12.5 mg/500 mg, 12.5 mg/850 mg, 12.5 mg/1000 mg tablets [product monograph]. Oakville (ON): Takeda Canada Inc; Nov 27, 2013.
16.
PrKomboglyze®: saxagliptin and metformin hydrochloride tablets (as saxagliptin hydrochloride and metformin hydrochloride): 2.5mg/500mg, 2.5mg/850mg, 2.5mg/1000mg [product monograph]. Mississauga (ON): AstraZeneca Canada Inc; Jun 30, 2013.
17.
PrJentadueto®: linaglitpin/metformin hydrochloride tablets 2.5 mg/500 mg and 2.5 mg/850 mg and 2.5 mg/1000 mg [product monograph]. Burlington (ON): Boehringer Ingelheim (Canada) Ltd; Feb 19, 2014.
18.
PrJanumet® XR: sitagliptin and metformin hydrochloride modified-release tablets (as sitagliptin phosphate monohydrate and metformin hydrochloride): 50 mg/500 mg, 50 mg/1000 mg, 100 mg/1000 mg [product monograph]. Kirkland (QC): Merck Canada Inc; Nov 21, 2013. PrJanumet®: sitagliptin and metformin hydrochloride tablets (as sitagliptin phosphate monohydrate and metformin hydrochloride): 50 mg/500 mg and 50 mg/850 mg and 50 mg/1000 mg.
19.
Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009 Jan;63(1):46–55. [PubMed: 19125992]
20.
Clinical study report: SYR-322-MET-008. Final report. A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of SYR110322 (SYR-322) when used in combination with metformin in subjects with type 2 diabetes [CONFIDENTIAL internal manufacturer's report]. Deerfield (IL): Takeda Global Research & Development Center, Inc; Oct 16, 2007.
21.
CDR submission: Kazano™ (alogliptin and metformin) 12.5 mg/500 mg, 12.5 mg/850 mg and 12.5 mg/1000 mg tablets. Company: Takeda Canada Inc. [CONFIDENTIAL manufacturer's submission]. Oakville (ON): Takeda Canada Inc; Dec, 2013.
22.
Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014 Jul;16(7):613–621. [PubMed: 24400655]
23.
Clinical study report: SYR-322MET_302. A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of alogliptin plus metformin, alogliptin alone, or metformin alone in subjects with type 2 diabetes [CONFIDENTIAL internal manufacturer's report]. Deerfield (IL): Takeda Global Research & Development Center, Inc; Oct 24, 2011.
24.
Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a two-year study. Diabetes Obes Metab. 2014 Aug 8 Epub ahead of print. [PubMed: 25132212]
25.
Final clinical study report: SYR-322_305. A multicenter, randomized, double-blind, active-controlled study to evaluate the durability of the efficacy and safety of alogliptin compared to glipizide when used in combination with metformin in subjects with type 2 diabetes [CONFIDENTIAL internal manufacturer's report]. Deerfield (IL): Takeda Global Research & Development Center, Inc; Mar 22, 2013.
26.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Kazano (alogliptin and metformin hydrochloride) tablets. Company: Takeda Pharmaceuticals U.S.A., Inc. Application no.: 203414. Approval date: 1/25/2013. Rockville (MD): The Center; Apr 18, 2014. [cited 2014 Jul 24]. Medical review(s) [Internet] (FDA drug approval package). Available from: http://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2013/203414Orig1s000TOC.cfm.
27.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Kazano (alogliptin and metformin hydrochloride) tablets. Company: Takeda Pharmaceuticals U.S.A., Inc. Application no.: 203414. Approval date: 1/25/2013. Rockville (MD): The Center; Apr 18, 2014. [cited 2014 Jul 24]. Statistical review(s) [Internet] (FDA drug approval package). Available from: http://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2013/203414Orig1s000TOC.cfm.
28.
Health Canada reviewer's report: Kazano (alogliptin benzoate and metformin hydrochloride) [CONFIDENTIAL internal report]. Ottawa: Therapeutics Products Directorate, Health Canada; 2013.
29.
Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [Internet]. London: European Medicines Agency; May 14, 2014. [cited 2014 Sep 24]. Available from: http://www​.ema.europa​.eu/docs/en_GB/document_library​/Scientific_guideline​/2012/06/WC500129256.pdf.
30.
Center for Drug Evaluation and Research. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention [Internet]. Silver Spring (MD): U.S. Department of Health and Human Services, Food and Drug Administration; Feb, 2008. [cited 2014 Sep 24]. Guidance for industry. Available from: http://www​.fda.gov/downloads​/Drugs/Guidances/ucm071624.pdf.
31.
Committee for Medicinal Products for Human Use. CHMP assessment report: Vipidia: international non-proprietary name: alogliptin [Internet]. London: European Medicines Agency; Jul 25, 2013. [cited 2014 Oct 1]. Available from: http://www​.ema.europa​.eu/docs/en_GB/document_library​/EPAR_-_Public​_assessment_report​/human/002182/WC500152273.pdf.
32.
Clinical study report: SYR-322-TZD-009. Final report. A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of SYR110322 (SYR-322) when used in combination with pioglitazone in subjects with type 2 diabetes [CONFIDENTIAL internal manufacturer's report]. Deerfield (IL): Takeda Global Research & Development Center, Inc; Nov 1, 2007.
33.
Clinical study report: SYR-322-INS-011. Final report. A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of SYR110322 (SYR-322) when used in combination with insulin in subjects with type 2 diabetes [CONFIDENTIAL internal manufacturer's report]. Deerfield (IL): Takeda Global Research & Development Center, Inc; Oct 12, 2007.
34.
Control Group. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009 Nov;52(11):2288–2298. [PubMed: 19655124]
35.
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ [Internet] 2011;343:d4169. [cited 2014 Oct 20]; Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC3144314. [PMC free article: PMC3144314] [PubMed: 21791495]
36.
Craddy P, Palin HJ, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther [Internet] 2014 Jun;5(1):1–41. [cited 2014 Aug 21]; Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC4065303/ [PMC free article: PMC4065303] [PubMed: 24664619]
37.
Tolley K, Kay S, Strickson A. Report for a systematic review and mixed treatment comparison of the clinical effectiveness and safety of alogliptin (Vipidia®) versus other DPP-4 inhibitors for the treatment of type 2 diabetes [CONFIDENTIAL additional manufacturer's information]. Version 1.0. Buxton (UK): Tolley Health Economics Ltd. for Takeda UK Ltd; May 19, 2014.
38.
Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. Silver Spring (MD): U.S. Department of Health and Human Services, Food and Drug Administration; Dec, 2008. [cited 2014 Sep 29]. Available from: http://www​.fda.gov/downloads​/Drugs/GuidanceComplianceRegulatoryInformation​/Guidances/ucm071627.pdf.
39.
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3;369(14):1327–1335. [PubMed: 23992602]
40.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3;369(14):1317–1326. [PubMed: 23992601]
41.
PrNesina™: alogliptin (as alogliptin benzoate): 6.25 mg, 12.5 mg and 25 mg tablets [product monograph]. Oakville (ON): Takeda Canada Inc; Nov 26, 2013.
42.
PrTrajenta®: linagliptin tablets: 5 mg [product monograph]. Burlington (ON): Boehringer Ingelheim (Canada) Ltd; Feb 19, 2014.
43.
PrOnglyza®: saxagliptin tablets (as saxagliptin hydrochloride: 2.5 and 5 mg [product monograph]. Mississauga (ON): AstraZeneca Canada Inc; Jun 30, 2014.
44.
PrJanuvia®: sitagliptin tablets (as sitagliptin phosphate monohydrate): 25, 50 and 100 mg [product monograph]. Kirkland (QC): Merck Canada Inc; Feb 18, 2014.
45.
Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med. 2014 Feb 27;370(9):794–797. [PubMed: 24571751]
46.
Canadian Diabetes Association annual report, 2013 [Internet]. Toronto: Canadian Diabetes Association; 2013. [cited 2015 Feb 26]. Available from: http://www​.diabetes.ca​/CDA/media/documents​/publications-and-newsletters​/annual-reports​/2013-cda-annual-report.pdf.
47.
Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence [Internet]. London: European Medicines Agency; Jan 20, 2010. [cited 2014 Oct 3]. Available from: http://www​.ema.europa​.eu/docs/en_GB/document_library​/Scientific_guideline​/2010/01/WC500070039.pdf.
48.
Allgemeine methoden [Internet]. Version 4.1. Cologne, Germany: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; Nov 28, 2013. [cited 2014 Sep 5]. Available from: https://www​.iqwig.de​/download/IQWiG_Methoden_Version_4-1.pdf.
49.
Guide d'analyse de la littérature et gradation des recommandations [Internet]. Paris: Agence Nationale d'Accréditation et d'Évaluation en Santé (ANAES); Jan, 2000. [cited 2014 Sep 5]. Available from: http://www​.has-sante​.fr/portail/upload/docs​/application/pdf/analiterat.pdf.
50.
National Institute for Health and Clinical Excellence. Guide to the single technology appraisal process [Internet]. London: NICE; Oct, 2009. [cited 2014 Sep 5]. Available from: https://www​.nice.org​.uk/resource/TA274/pdf​/c/nice-gives-green-light-to-ranibizumab-for-diabetic-macular-oedema-in-final-guidance-after-rapid-review.
51.
CONSORT [Internet]. Ottawa (ON): The CONSORT Group; 2014. [cited 2014 Sep 5]. Available from: http://www​.consort-statement.org/
52.
Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999 Jun;18(3):341–364. [PubMed: 10537899]
53.
Final clinical study report: SYR-322_402. A multicenter, randomized, double-blind, placebo-controlled study to evaluate cardiovascular outcomes following treatment with alogliptin in addition to standard of care in subjects with type 2 diabetes and acute coronary syndrome [CONFIDENTIAL internal manufacturer's report]. Deerfield (IL): Takeda Development Center Americas, Inc; Nov 4, 2013.
Copyright © CADTH 2015.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK349235
Contents

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
-